Epigenetic modification in radiotherapy and immunotherapy for cancers
Radiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients. However, several issues in conducting RIT are challenging, such as incorporat...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-09-01
|
| Series: | Tzu Chi Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/tcmj.tcmj_3_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157710976221184 |
|---|---|
| author | Shih-Kai Hung Moon-Sing Lee Wen-Yen Chiou Dai-Wei Liu Chih-Chia Yu Liang-Cheng Chen Ru-Inn Lin Chia-Hui Chew Feng-Chun Hsu Hsuan-Ju Yang Michael W. Y. Chan Hon-Yi Lin |
| author_facet | Shih-Kai Hung Moon-Sing Lee Wen-Yen Chiou Dai-Wei Liu Chih-Chia Yu Liang-Cheng Chen Ru-Inn Lin Chia-Hui Chew Feng-Chun Hsu Hsuan-Ju Yang Michael W. Y. Chan Hon-Yi Lin |
| author_sort | Shih-Kai Hung |
| collection | DOAJ |
| description | Radiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients. However, several issues in conducting RIT are challenging, such as incorporating advanced irradiation techniques, predictive/prognostic biomarkers, and other treatment modalities. Several clinical efforts and novel biomarkers have been introduced and developed to solve these challenges. For example, stereotactic radiosurgery/stereotactic radiotherapy, stereotactic body radiotherapy/stereotactic ablative body radiotherapy, and FLASH-RT have been applied for delivering precise irradiation to lung and liver tumors in conjunction with IT. Besides, several novel IT agents and incorporations of other therapies, such as targeted and thermal therapies, have been further investigated. The present study reviewed the emerging challenges of RIT in modern oncology. We also evaluated clinical practice, bench research, and multimodality treatments. In addition to several clinically applicable biomarkers, we emphasize the roles of advanced irradiation techniques and epigenetic modification as predictive/prognostic biomarkers and potential therapeutic targets. For example, 6(m) A-based epigenetic agents demonstrate the potential to enhance the treatment effects of RIT. However, further prospective randomized trials should be conducted to confirm their roles. |
| format | Article |
| id | doaj-art-344da1cb41cc4102a18f8aefa47030ea |
| institution | OA Journals |
| issn | 1016-3190 2223-8956 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Tzu Chi Medical Journal |
| spelling | doaj-art-344da1cb41cc4102a18f8aefa47030ea2025-08-20T02:24:05ZengWolters Kluwer Medknow PublicationsTzu Chi Medical Journal1016-31902223-89562024-09-0136439640610.4103/tcmj.tcmj_3_24Epigenetic modification in radiotherapy and immunotherapy for cancersShih-Kai HungMoon-Sing LeeWen-Yen ChiouDai-Wei LiuChih-Chia YuLiang-Cheng ChenRu-Inn LinChia-Hui ChewFeng-Chun HsuHsuan-Ju YangMichael W. Y. ChanHon-Yi LinRadiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients. However, several issues in conducting RIT are challenging, such as incorporating advanced irradiation techniques, predictive/prognostic biomarkers, and other treatment modalities. Several clinical efforts and novel biomarkers have been introduced and developed to solve these challenges. For example, stereotactic radiosurgery/stereotactic radiotherapy, stereotactic body radiotherapy/stereotactic ablative body radiotherapy, and FLASH-RT have been applied for delivering precise irradiation to lung and liver tumors in conjunction with IT. Besides, several novel IT agents and incorporations of other therapies, such as targeted and thermal therapies, have been further investigated. The present study reviewed the emerging challenges of RIT in modern oncology. We also evaluated clinical practice, bench research, and multimodality treatments. In addition to several clinically applicable biomarkers, we emphasize the roles of advanced irradiation techniques and epigenetic modification as predictive/prognostic biomarkers and potential therapeutic targets. For example, 6(m) A-based epigenetic agents demonstrate the potential to enhance the treatment effects of RIT. However, further prospective randomized trials should be conducted to confirm their roles.https://journals.lww.com/10.4103/tcmj.tcmj_3_24epigenetic modificationimmunotherapyoutcome predictionradiotherapytoxicity |
| spellingShingle | Shih-Kai Hung Moon-Sing Lee Wen-Yen Chiou Dai-Wei Liu Chih-Chia Yu Liang-Cheng Chen Ru-Inn Lin Chia-Hui Chew Feng-Chun Hsu Hsuan-Ju Yang Michael W. Y. Chan Hon-Yi Lin Epigenetic modification in radiotherapy and immunotherapy for cancers Tzu Chi Medical Journal epigenetic modification immunotherapy outcome prediction radiotherapy toxicity |
| title | Epigenetic modification in radiotherapy and immunotherapy for cancers |
| title_full | Epigenetic modification in radiotherapy and immunotherapy for cancers |
| title_fullStr | Epigenetic modification in radiotherapy and immunotherapy for cancers |
| title_full_unstemmed | Epigenetic modification in radiotherapy and immunotherapy for cancers |
| title_short | Epigenetic modification in radiotherapy and immunotherapy for cancers |
| title_sort | epigenetic modification in radiotherapy and immunotherapy for cancers |
| topic | epigenetic modification immunotherapy outcome prediction radiotherapy toxicity |
| url | https://journals.lww.com/10.4103/tcmj.tcmj_3_24 |
| work_keys_str_mv | AT shihkaihung epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT moonsinglee epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT wenyenchiou epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT daiweiliu epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT chihchiayu epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT liangchengchen epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT ruinnlin epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT chiahuichew epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT fengchunhsu epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT hsuanjuyang epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT michaelwychan epigeneticmodificationinradiotherapyandimmunotherapyforcancers AT honyilin epigeneticmodificationinradiotherapyandimmunotherapyforcancers |